Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design
Source abstract
Abstract
CAR T cell therapy represents a leading therapeutic modality in the treatment of hematological cancers. However, conventional ex vivo manufacturing processes are extremely complex, costly, and time-consuming. Hence, in vivo CAR-T cell therapy represents a promising alternative, where T cells are genetically modified directly within the patient. This novel approach requires the careful design of three modular and interdependent nanoscale parameters: CAR architecture, targeted lipid nanoparticle delivery systems, and nucleic acid cargo format. Each component is highly modular, therefore systematic optimization can enhance the safety and efficacy of in vivo CAR T cell generation. Here, we review the molecular and mechanistic principles underlying this therapeutic strategy, emphasizing how these nanoscale design features govern CAR T cell production and functional performance in vivo. Advancing our understanding of these parameters is critical to developing efficient, safe, and clinically translatable in vivo CAR T cell cancer therapies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: CAR-T cell therapy research · Monoclonal and Polyclonal Antibodies Research · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
CDL Research, Division LAB, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
Metabolic Diseases Research, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Lundlaan 6, 3584 EA Utrecht, The Netherlands
Regenerative Medicine Center Utrecht, Uppsalalaan 8, 3584 EA Utrecht, The Netherlands
Nanocell Therapeutics BV, Yalelaan 62, 3584 CM Utrecht, The Netherlands
Funding
HORIZON EUROPE European Research Council · Health~Holland
References (56)
Show source-provided references
1. 10.3892/br.2025.197210.3892/br.2025.1972 ↗
2. 10.1038/s41392-025-02280-110.1038/s41392-025-02280-1 ↗
3. 10.3389/fimmu.2023.132159610.3389/fimmu.2023.1321596 ↗
4. 10.1186/s13046-022-02327-z10.1186/s13046-022-02327-z ↗
5. 10.1016/j.nantod.2023.10180510.1016/j.nantod.2023.101805 ↗
6. 10.1186/s40364-022-00364-610.1186/s40364-022-00364-6 ↗
7. 10.1016/j.copbio.2018.01.02510.1016/j.copbio.2018.01.025 ↗
8. 10.1016/j.yexcr.2021.11297110.1016/j.yexcr.2021.112971 ↗
9. 10.1136/jitc-2025-01175910.1136/jitc-2025-011759 ↗
10. 10.1016/j.ymthe.2022.05.01810.1016/j.ymthe.2022.05.018 ↗
11. 10.1002/jha2.33810.1002/jha2.338 ↗
12. 10.1038/s41586-023-05707-310.1038/s41586-023-05707-3 ↗
13. 10.1089/hum.2017.11510.1089/hum.2017.115 ↗
14. 10.1038/s41467-022-34141-810.1038/s41467-022-34141-8 ↗
15. 10.1038/s41587-019-0329-210.1038/s41587-019-0329-2 ↗
16. 10.1126/science.abm059410.1126/science.abm0594 ↗
17. 10.1038/s41584-024-01139-z10.1038/s41584-024-01139-z ↗
18. 10.1056/NEJMoa230891710.1056/NEJMoa2308917 ↗
19. 10.1016/j.ymthe.2020.08.00310.1016/j.ymthe.2020.08.003 ↗
20. 10.3390/cells905118210.3390/cells9051182 ↗
21. 10.1080/2162402X.2016.125365610.1080/2162402X.2016.1253656 ↗
22. 10.1089/hum.2020.21610.1089/hum.2020.216 ↗
23. 10.1186/s12896-023-00827-010.1186/s12896-023-00827-0 ↗
24. 10.3389/fimmu.2025.153134410.3389/fimmu.2025.1531344 ↗
25. 10.1126/sciadv.adp400810.1126/sciadv.adp4008 ↗
26. 10.1038/s41551-022-00896-010.1038/s41551-022-00896-0 ↗
27. 10.1126/scitranslmed.abm146310.1126/scitranslmed.abm1463 ↗
28. 10.1126/science.abq022510.1126/science.abq0225 ↗
29. 10.1016/j.ymthe.2022.07.00710.1016/j.ymthe.2022.07.007 ↗
30. 10.1016/j.jconrel.2022.08.03310.1016/j.jconrel.2022.08.033 ↗
31. 10.1038/s41467-020-19486-210.1038/s41467-020-19486-2 ↗
32. 10.1002/smll.20230437810.1002/smll.202304378 ↗
33. 10.1038/s41577-025-01174-110.1038/s41577-025-01174-1 ↗
34. 10.15252/emmm.20180915810.15252/emmm.201809158 ↗
35. 10.1016/j.cellimm.2018.04.01210.1016/j.cellimm.2018.04.012 ↗
36. 10.1038/s41408-021-00508-110.1038/s41408-021-00508-1 ↗
37. 10.1038/nnano.2017.5710.1038/nnano.2017.57 ↗
38. 10.1089/hum.2024.10610.1089/hum.2024.106 ↗
39. 10.1073/pnas.220784111910.1073/pnas.2207841119 ↗
40. 10.1016/j.ymthe.2021.06.00410.1016/j.ymthe.2021.06.004 ↗
41. 10.1016/j.biomaterials.2021.12133910.1016/j.biomaterials.2021.121339 ↗
42. 10.1021/acs.nanolett.0c0138610.1021/acs.nanolett.0c01386 ↗
43. 10.1039/D0BM01609H10.1039/D0BM01609H ↗
44. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
45. 10.1021/acs.biomac.7b0008010.1021/acs.biomac.7b00080 ↗
46. 10.1038/mtna.2013.6610.1038/mtna.2013.66 ↗
47. 10.1038/mtna.2014.6110.1038/mtna.2014.61 ↗
48. 10.3390/pharmaceutics1312209710.3390/pharmaceutics13122097 ↗
49. 10.1021/bc200621910.1021/bc2006219 ↗
50. 10.1038/s41565-021-00928-x10.1038/s41565-021-00928-x ↗
51. 10.1002/adma.20190612810.1002/adma.201906128 ↗
52. 10.1016/j.jconrel.2020.01.03510.1016/j.jconrel.2020.01.035 ↗
53. 10.1101/2024.12.20.62946710.1101/2024.12.20.629467 ↗
54. 10.1016/j.ijpharm.2022.12174110.1016/j.ijpharm.2022.121741 ↗
55. 10.1021/acsnano.1c0827710.1021/acsnano.1c08277 ↗
56. 10.1084/jem.2023090310.1084/jem.20230903 ↗